Eramkafusp Biosimilar Antibody Fusion Protein (CD20) for Research

Cat No.: GMP-Bios-ab-192

Pre-Made Eramkafusp biosimilar, Whole mAb Fusion, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.



Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-ab-192-1mg 1mg
GMP-Bios-ab-192-10mg 10mg
GMP-Bios-ab-192-100mg 100mg
GMP-Bios-ab-192-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Eramkafusp biosimilar, Whole mAb Fusion, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
INN Name Eramkafusp
TargetMS4A1
FormatWhole mAb Fusion
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone
99% SI Structure2osl:AB:HL/4kaq:HL
95-98% SI StructureNone
Year Proposed2020
Year Recommendedna
CompaniesSpectrum Pharmaceuticals;ImmunGene
Conditions Approvedna
Conditions ActiveNon-Hodgkin's lymphoma
Conditions Discontinuedna
Development Techna